Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round - Lundbeckfonden
![Thomas Holm Pedersen - Chief Executive Officer, Associate professor of Physiology and Biophysics in Aarhus, Arhus, Denmark | eMedEvents Thomas Holm Pedersen - Chief Executive Officer, Associate professor of Physiology and Biophysics in Aarhus, Arhus, Denmark | eMedEvents](https://d3p2qewzsoh75c.cloudfront.net/uploads/conferences/logo/200/hanson_wade_1562142726.jpg)
Thomas Holm Pedersen - Chief Executive Officer, Associate professor of Physiology and Biophysics in Aarhus, Arhus, Denmark | eMedEvents
![NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis](https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo.png)
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
![NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis](https://www.globalbankingandfinance.com/category/news/wp-content/uploads/2019/07/gbafNews28-1000x600.jpg)
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
![NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis](https://benzinga-amp-cdn.s3.amazonaws.com/Benzinga-Logo-onecolor-white.png)